Latest Breaking News On - Oncology at leuven cancer institute - Page 1 : comparemela.com

The oral MDM2/p53 antagonist BI 907828 elicited preliminary antitumor activity and had a manageable safety profile in patients with MDM2-amplified dedifferentiated liposarcoma.

Region flamandePatrick schoffskiActa biochim biophysUniversity hospitals leuvenBoehringer ingelheimRare cancers congressOncology at leuven cancer instituteRare cancersGeneral medical oncologyLeuven cancer instituteSartar therapeuticsEllipses pharmaMerck healthcareBiochim biophys sinSarcomas tgct2023 esmo sarcoma and rare cancers congress